Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of a Single Escalating Dose of PER977 Following Administration of Unfractionated Heparin
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2017
Price : $35 *
At a glance
- Drugs Ciraparantag (Primary)
- Indications Haemorrhage
- Focus Therapeutic Use
- Sponsors Perosphere
- 25 Sep 2017 Status changed from active, no longer recruiting to completed.
- 23 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 18 Dec 2014 Additional study cohorts 5 and 6 for doses 500 mg and 600 mg are added in treatment table. Planned number of patients also changed from 40 to 60 as reported by ClinicalTrials.gov record.